BUSM researcher receives prestigious Massachusetts Neuroscience Consortium award

December 05, 2014

(Boston)--Carmela Abraham, PhD, professor of biochemistry and pharmacology at Boston University School of Medicine, was one of six recipients of this year's Massachusetts Neuroscience Consortium Award out of nearly 60 applicants. The grant was awarded to her for her work on multiple sclerosis and the role of the life extension protein Klotho in the limited repair of white matter in the disease.

The Consortium gives the award to those doing translational research in neurodegenerative and neuroinflammatory diseases--such as Amyotrophic Lateral Sclerosis, Alzheimer's disease, Huntington's disease, Multiple sclerosis, Parkinson's disease, neuropathic pain and treatment-resistant depression.

Although Abraham has devoted her entire career to the study of the molecular mechanisms leading to normal brain aging and the pathological processes that culminate in Alzheimer's, she discovered that Klotho is a neuroprotective protein that has beneficial effects in animal models of both Alzheimer's and multiple sclerosis. Since Klotho is significantly reduced in the brain during normal aging and in Alzheimer's disease, Abraham and her colleagues searched for and identified molecules that can increase Klotho levels in the brain. She is hoping to exploit these molecules to create new treatments to prevent brain aging, neurodegenerative and neuroinflammatory diseases.

Abraham received her Bachelor of Science in biology from Tel Aviv University and her PhD in neuroscience from Harvard University. In addition to winning this award, she is the recipient of The Neuroscience Education and Research Foundation Award for an Outstanding Promise as a Young Alzheimer Investigator (1990). She has received two of the highest awards from the Alzheimer's Association - The Zenith Award (1994) and the Temple Award (1999).

The Consortium was founded in 2012 by Massachusetts Life Sciences as a way to bring together researchers, private companies and the government in order to accelerate budding translational neuroscience research. Participating companies include AbbVie, Biogen Idec, EMD Serono, Janssen Research & Development, Merck, Pfizer and Sunovion Pharmaceuticals. Each company pledged money to support the grant winners, totaling $1.5 million.
-end-


Boston University Medical Center

Related Multiple Sclerosis Articles from Brightsurf:

New therapy improves treatment for multiple sclerosis
A new therapy that binds a cytokine to a blood protein shows potential in treating multiple sclerosis, and may even prevent it.

'Reelin' in a new treatment for multiple sclerosis
In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

New therapeutic options for multiple sclerosis in sight
Strategies for treating multiple sclerosis have so far focused primarily on T and B cells.

Diet has an impact on the multiple sclerosis disease course
The short-chain fatty acid propionic acid influences the intestine-mediated immune regulation in people with multiple sclerosis (MS).

The gut may be involved in the development of multiple sclerosis
It is incompletely understood which factors in patients with multiple sclerosis act as a trigger for the immune system to attack the brain and spinal cord.

Slowing the progression of multiple sclerosis
Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown.

7T MRI offers new insights into multiple sclerosis
Investigators from Brigham and Women's Hospital have completed a new study using 7 Tesla (7T) MRI -- a far more powerful imaging technology -- to further examine LME in MS patients

How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.

Vaccinations not a risk factor for multiple sclerosis
Data from over 12,000 multiple sclerosis (MS) patients formed the basis of a study by the Technical University of Munich (TUM) which investigated the population's vaccination behavior in relation to MS.

Read More: Multiple Sclerosis News and Multiple Sclerosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.